{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_text": "The three mutations (A30P, E46K, A53T) are associated with early-onset PD, and the proteasome cleavage of αSyn leads to fragments that accelerate fibrillization and oligomer formation.",
          "judgment": "The paper links αSyn processing (proteasome cleavage) to PD pathology, with the mutations affecting oligomer formation, a key pathogenic mechanism."
        },
        {
          "step_name": "Step 2: Evaluate applicability of the assay",
          "extracted_text": "The proteasome cleavage and subsequent oligomer formation are used to model the disease mechanism.",
          "judgment": "The assay (proteasome activity) is relevant to the disease mechanism of αSyn processing."
        },
        {
          "step_name": "Step 3: Evaluate validity of the assay",
          "extracted_text": "The paper does not mention controls (wildtype vs. mutant) or replicates, but the proteasome cleavage is demonstrated in vitro.",
          "judgment": "The assay is a known method (proteasome activity), but no prior validation is cited, leading to Max PS3_supporting."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_text": "The rate of oligomer formation correlates with the mutations, but no statistical tests are provided.",
          "judgment": "No statistical analysis is performed, leading to Max PS3_supporting."
        }
      ],
      "evidence_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "E",
          "alt": "K",
          "position": "46"
        },
        "variant_string_id": "SNCA E46K"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_text": "The mutations affect αSyn processing, leading to fragments that accelerate fibrillization and oligomer formation.",
          "judgment": "The paper links αSyn processing to PD pathology, with the mutations affecting oligomer formation."
        },
        {
          "step_name": "Step 2: Evaluate applicability of the assay",
          "extracted_text": "The proteasome cleavage and subsequent oligomer formation are used to model the disease mechanism.",
          "judgment": "The assay is relevant to the disease mechanism of αSyn processing."
        },
        {
          "step_name": "Step 3: Evaluate validity of the assay",
          "extracted_text": "The paper does not mention controls (wildtype vs. mutant) or replicates, but the proteasome cleavage is demonstrated in vitro.",
          "judgment": "The assay is a known method (proteasome activity), but no prior validation is cited, leading to Max PS3_supporting."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_text": "The rate of oligomer formation correlates with the mutations, but no statistical tests are provided.",
          "judgment": "No statistical analysis is performed, leading to Max PS3_supporting."
        }
      ],
      "evidence_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_text": "The mutations affect αSyn processing, leading to fragments that accelerate fibrillization and oligomer formation.",
          "judgment": "The paper links αSyn processing to PD pathology, with the mutations affecting oligomer formation."
        },
        {
          "step_name": "Step 2: Evaluate applicability of the assay",
          "extracted_text": "The proteasome cleavage and subsequent oligomer formation are used to model the disease mechanism.",
          "judgment": "The assay is relevant to the disease mechanism of αSyn processing."
        },
        {
          "step_name": "Step 3: Evaluate validity of the assay",
          "extracted_text": "The paper does not mention controls (wildtype vs. mutant) or replicates, but the proteasome cleavage is demonstrated in vitro.",
          "judgment": "The assay is a known method (proteasome activity), but no prior validation is cited, leading to Max PS3_supporting."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_text": "The rate of oligomer formation correlates with the mutations, but no statistical tests are provided.",
          "judgment": "No statistical analysis is performed, leading to Max PS3_supporting."
        }
      ],
      "evidence_strength": "PS3_supporting"
    }
  ]
}